Humans need to maintain an adequate dietary intake of folate during various stages of their lives. Relevant clinical research emphasizes the importance of folate supplementation in different therapeutic areas such as neural-tube defect, male and female infertility, spontaneous abortion, coronary heart disease, macrocytic anemia, methotrexate therapy.

Folate deficiency is related to the reduction of a cell's capacity to synthesize and repair DNA. Eating folate-rich foods may not provide the recommended daily dosage; thus the need for supplementation. In recent years evidence has shown that reduced folate supplementation present relevant advantages vs folic acid. The rational use of such reduced folates (particularly reduced and methylated) is derived from the inability of a part of world's population to assimilate and metabolize folic acid from food or supplements.

The multidisciplinary research team at Gnosis has intensely researched this category of products and today Gnosis is the only manufacturer of three folate products that can claim GRAS status and NDIN with advanced chemical and clinical characteristics.

In February 2008, Gnosis patented the new generation of folate derivative, brand named Quatrefolic®,
endowed with a long lasting stability and a peculiarly high water solubility as well as an improved bioavailability and established safety. Quatrefolic® is the glucosamine salt of (6S)-5-methyltetrahydrofolate and is structurally analogous to the reduced and nutritionally active form of folic acid, 5-methyltetrahydrofolate.

The goal for Gnosis' R&D was to develop an innovative folate salt form able to overcome the existing calcium salt form limitations related to stability and poor solubility.

Until now folate deficiency has been characterized by supplementation of folates (first generation), through folic acid (second generation) up to 5-methyltetrahydrofolate calcium salt (third generation), the only folic acid derivative available on the market able to penetrate the body cells without further metabolism.

Gnosis now makes available for market Quatrefolic®, the fourth generation folate hitting the target of the most bioavailable methylated reduced folate.

> Technical Information
Grade: Oral
Packing size: 1kg, 5 kg LDPE bags
Regulatory status: GRAS, NDI
Chemical name:
N‐[4‐[[[(6S)‐2‐amino‐1,4,5,6,7,8‐hexahydro‐5‐methyl‐4‐oxo‐6‐pteridinyl]methyl]amino]benzoyl]‐L‐glutamic acid, glucosamine salt.

The key benefits of Quatrefolic® allowing the product to be suitable for dietary supplements as well as food and beverage uses and in combination of different vitamins and minerals.

The unique room temperature stability profile makes it easier to handle in all facets of commercialization, development, manufacturing, and consumer products. Quatrefolic® is the first innovation in this category in the last 10 years, it has proven improved human bioavailability and stability and is protected by extensive IP.

For more information please visit